AzTrials
AzTrials

Neurodevelopmental Disorder (Diagnosis)DIS-NeurodevNCT06877260

Characterization of Neurocognitive Profiles in Neurodevelopmental Disorders and Epilepsy: a Transdiagnostic Approach

An observational study of Neurodevelopmental Disorder (Diagnosis) and Epilepsy, run by IRCCS Eugenio Medea at 1 site in Italy.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Neurodevelopmental disorders (NDDs) are early-onset conditions affecting personal, social, and academic functioning, with high comorbidity rates and shared neurobiological traits. Read more about this study

Who is it for?
Ages 6 to 17 yearsHealthy volunteers can take part
What is being tested?
Computer based task with EEG
How many people
60 participants
Where
1 siteItaly
Study dates
1 Nov 2024to 1 Nov 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 17 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: Patients with diagnosis of neurodevelopmental disorders

Who may be able to join

  • Age between 6 and 16 years at the time of the study assessment.
  • Participant's ability to collaborate in performing computerized cognitive tasks.
  • Ability to undergo a neuropsychological assessment in the Italian language

Who cannot join

  • Presence of organic disorders such as previous ischemic events, cerebral neoplastic elements, or a clinical history including brain surgery.
  • Age outside the 6-16 years range.
  • Inability to perform computerized cognitive tasks.
  • Inability to undergo a neuropsychological assessment in the Italian language.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • IRCC E.Medea

    Conegliano, Italy/Treviso, 31015

Other trials in Italy

About this study

Neurodevelopmental disorders (NDDs) are early-onset conditions affecting personal, social, and academic functioning, with high comorbidity rates and shared neurobiological traits. Traditional diagnostic categories struggle to explain symptom overlap, supporting a transdiagnostic approach that views NDDs as dimensions rather than distinct entities.

This project aims to identify common neuropsychological and neurophysiological profiles in ADHD, autism, intellectual disability, and learning disorders using high-density EEG and cognitive tasks assessing cognitive control. By integrating neuropsychological assessments, EEG responses, and behavioral data, the study seeks to identify shared functional profiles rather than disorder-specific biomarkers.

Additionally, it will analyze the relationship between NDDs and epilepsy to validate behavioral and neurophysiological markers. Conducted in collaboration with the University of Padua, the study employs advanced data analysis to enhance personalized interventions.

Read the detailed description

Neurodevelopmental disorders (NDDs) are a heterogeneous group of clinically significant conditions that emerge in early childhood, leading to mild to severe impairments in personal, social, and academic functioning, negatively impacting quality of life. Up to 10% of children are diagnosed with one or more NDDs. Epilepsy is one of the most common neurological comorbidities associated with NDDs.

Traditional categorical diagnoses have shaped scientific research under the assumption that each NDD category is characterized by specific neurocognitive and biological markers. However, current classification systems struggle to explain the symptomatic overlap observed among disorders traditionally considered distinct in their etiology. In fact, comorbidity among different NDDs is more common than the exception. For instance, learning disorders are present in 44% of children with ADHD and 65-85% of autistic children, while ADHD and autism have comorbidity rates ranging from 30% to 70%. Recent neuroimaging studies have also demonstrated that structural and functional neural patterns are shared across multiple NDDs, concluding that no disorder-specific biomarkers could be identified in large patient cohorts.

These clinical findings suggest adopting an alternative transdiagnostic approach, considering NDDs in terms of dimensions rather than categories. A deeper understanding of the shared neural, behavioral, and biological mechanisms among NDDs could scientifically validate the shift from a category-based to a dimensional approach, emphasizing individual neurocognitive variability and improving therapeutic efficacy.

Aligned with the transdiagnostic paradigm, this project aims to characterize the neuropsychological and neurophysiological profiles of certain NDDs (i.e., attention-deficit/hyperactivity disorder (ADHD), autism, intellectual disability, language and learning disorders). The presence of common neurocognitive profiles across diagnostic categories will be investigated using high-density EEG in both resting-state conditions and during specific computerized cognitive tasks. Specifically, these tasks will assess the ability to flexibly adapt cognitive control (CC) to environmental demands. Cognitive control refers to the set of mental abilities required to regulate thoughts, emotions, and behavior based on external demands and internal motivational states. It includes processes such as inhibition, working memory, cognitive flexibility, and planning-executive functions that are essential for self-regulation and often impaired in many NDDs. Thus, investigating CC across different diagnostic groups is crucial for developing intervention protocols tailored to individual needs rather than categorical diagnoses.

A battery of tests and questionnaires, part of the routine neuropsychological assessment administered to all patients at the IRCCS E. Medea "La Nostra Famiglia" center, will be given to both patients and their families. Additionally, participants will complete a computerized behavioral task (Mario task) and a second computerized task while undergoing electroencephalogram (EEG) recording (Flanker task). Administering both tasks allows for understanding how predictive context modulates the ability to inhibit inappropriate actions (Mario task) and manage cognitive conflict in the presence of distractor stimuli (Flanker task). The details of the questionnaires and computerized tasks will be described in the "Experimental Protocol" section.

The integration of various computerized cognitive tasks with neurophysiological measures will enable the creation of a multidimensional profile for each participant, encompassing the evaluation of brain network flexibility and organization at rest, EEG responses to cognitive tasks, and neuropsychological assessment outcomes. A dimensionality reduction approach will be applied to the data to identify separable clusters of neurocognitive functioning, characterized not only by neural organization and neuropsychological performance but also by environmental factors (e.g., socioeconomic indicators). In this framework, the goal is not to identify population-specific neurocognitive markers but rather shared (transdiagnostic) functional profiles that can define an individual's characteristics independently of their diagnostic category.

Additionally, analyzing shared and specific profiles among individuals with NDDs with or without epilepsy and, conversely, among individuals with epilepsy with or without an NDD diagnosis, represents a powerful validation tool for behavioral and neurophysiological markers.

This project, in line with the Framework Agreement (IRCCS-University Platform) approved by the Ministry of Health on May 3, 2023 (Id MIUR 4525), involves collaboration with the Department of General Psychology at the University of Padova. This collaboration aims to apply advanced data analysis techniques to both EEG signals and behavioral data (neuropsychological assessment and tasks)

Being tested
Computer based task with EEG
Keywords
transdiagnostic approach, neural fingerprint, neurodevelopmental disorders
Medical subject headings
Neurodevelopmental Disorders, Disease, Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Computer based task with EEGDiagnostic test

    Participants will undergo EEG recording while performing a computer based neuropsychological task evaluating cognitive control

Study groups in NCT06877260
Study groupRoleWhat they receive
Neuropsychological EEG testingPatients will undergo an EEG and neuropsycholgical tasks evaluation, as well as the control group
Receives: Diagnostic Test: Computer based task with EEG

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. EEG amplitude variation

    EEG evoked potentials amplitude measured in micronvolt

    Measured: Through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Mar 2025
  2. Study start1 Nov 2024
  3. Primary completion1 Sep 2025 (estimated)
  4. Study completion1 Nov 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06877260
Sponsor's protocol ID
1081
Acronym
DIS-Neurodev
Status last verified
Mar 2025
First submitted
26 Feb 2025
Last updated
14 Mar 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Duma GM, Di Bono MG, Mento G. Grounding Adaptive Cognitive Control in the Intrinsic, Functional Brain Organization: An HD-EEG Resting State Investigation. Brain Sci. 2021 Nov 15;11(11):1513. doi: 10.3390/brainsci11111513.

    PubMed 34827511
  • Dalgleish T, Black M, Johnston D, Bevan A. Transdiagnostic approaches to mental health problems: Current status and future directions. J Consult Clin Psychol. 2020 Mar;88(3):179-195. doi: 10.1037/ccp0000482.

    PubMed 32068421
  • Joshi G, Faraone SV, Wozniak J, Tarko L, Fried R, Galdo M, Furtak SL, Biederman J. Symptom Profile of ADHD in Youth With High-Functioning Autism Spectrum Disorder: A Comparative Study in Psychiatrically Referred Populations. J Atten Disord. 2017 Aug;21(10):846-855. doi: 10.1177/1087054714543368. Epub 2014 Aug 1.

    PubMed 25085653
  • Astle DE, Holmes J, Kievit R, Gathercole SE. Annual Research Review: The transdiagnostic revolution in neurodevelopmental disorders. J Child Psychol Psychiatry. 2022 Apr;63(4):397-417. doi: 10.1111/jcpp.13481. Epub 2021 Jul 23.

    PubMed 34296774

Questions about this trial

What is this clinical trial studying?

An observational study of Neurodevelopmental Disorder (Diagnosis) and Epilepsy, run by IRCCS Eugenio Medea at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 14 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

EEG amplitude variation (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06877260, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2025; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in